113 related articles for article (PubMed ID: 14756545)
21. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
Trento LK; Pietropolli A; Ticconi C; Gravotta E; De Martino MU; Fabbri A; Piccione E
J Obstet Gynaecol Res; 2009 Feb; 35(1):152-9. PubMed ID: 19215563
[TBL] [Abstract][Full Text] [Related]
22. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y
Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265
[TBL] [Abstract][Full Text] [Related]
23. Comparison of bone and total alkaline phosphatase activity on bone turnover during menopause and in patients with established osteoporosis.
Takahashi M; Kushida K; Hoshino H; Miura M; Ohishi T; Inoue T
Clin Endocrinol (Oxf); 1997 Aug; 47(2):177-83. PubMed ID: 9302392
[TBL] [Abstract][Full Text] [Related]
24. Retinol-binding protein 4 is positively associated with bone mineral density in patients with type 2 diabetes and osteopenia or osteoporosis.
Huang N; Zhou J; Wang W; Wang Q; Tang Y; Sun Y; Wang D; Chen S
Clin Endocrinol (Oxf); 2018 May; 88(5):659-664. PubMed ID: 29394455
[TBL] [Abstract][Full Text] [Related]
25. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
26. Bone mineral density and bone turnover in patients with psoriatic arthritis.
Borman P; Babaoğlu S; Gur G; Bingol S; Bodur H
Clin Rheumatol; 2008 Apr; 27(4):443-7. PubMed ID: 17876648
[TBL] [Abstract][Full Text] [Related]
27. Clinical usefulness of bone alkaline phosphatase in osteoporosis.
Kyd PA; Vooght KD; Kerkhoff F; Thomas E; Fairney A
Ann Clin Biochem; 1998 Nov; 35 ( Pt 6)():717-25. PubMed ID: 9838984
[TBL] [Abstract][Full Text] [Related]
28. New Markers of Bone Fragility in Hemodialysis Patients: A Monocentric Study.
Slouma M; Aissaoui T; Abbes M; Bahlous A; Laadhar L; Smaoui W; Gharsallah I; Ben Moussa F; Elleuch M; Sahli H; Cheour E
J Clin Densitom; 2021; 24(1):22-27. PubMed ID: 33288423
[TBL] [Abstract][Full Text] [Related]
29. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
Díaz-Martín MA; Traba ML; De La Piedra C; Guerrero R; Méndez-Dávila C; De La Peña EG
Scand J Clin Lab Invest; 1999 Apr; 59(2):125-32. PubMed ID: 10353326
[TBL] [Abstract][Full Text] [Related]
30. [Bone metabolism as assessed with selected markers of bone turnover as well as densitometry analysis in patients after successful kidney transplantation].
Giza D; Stompór T; Katra B; Sieradzki J; Sułowicz W
Przegl Lek; 2001; 58(11):979-84. PubMed ID: 11987839
[TBL] [Abstract][Full Text] [Related]
31. Relationship between bone mineral density and biochemical markers of bone turnover in hemodialysis patients.
Sit D; Kadiroglu AK; Kayabasi H; Atay AE; Yilmaz Z; Yilmaz ME
Adv Ther; 2007; 24(5):987-95. PubMed ID: 18029324
[TBL] [Abstract][Full Text] [Related]
32. Characteristics of bone turnover markers in rapidly destructive coxopathy.
Abe H; Sakai T; Ogawa T; Takao M; Nishii T; Nakamura N; Sugano N
J Bone Miner Metab; 2017 Jul; 35(4):412-418. PubMed ID: 27550182
[TBL] [Abstract][Full Text] [Related]
33. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of osteopenia and osteoporosis by central and peripheral bone mineral density in men with prostate cancer during androgen-deprivation therapy.
Bruder JM; Ma JZ; Basler JW; Welch MD
Urology; 2006 Jan; 67(1):152-5. PubMed ID: 16413352
[TBL] [Abstract][Full Text] [Related]
35. Osteoporosis during continuous androgen deprivation: influence of the modality and length of treatment.
Morote J; Martinez E; Trilla E; Esquena S; Abascal JM; Encabo G; Reventós J
Eur Urol; 2003 Dec; 44(6):661-5. PubMed ID: 14644117
[TBL] [Abstract][Full Text] [Related]
36. [Alkaline phosphatase of bone origin in hemodialyzed patients. 110 assays].
Ureña P; Prieur P; Pétrover M
Presse Med; 1996 Oct; 25(29):1320-5. PubMed ID: 8942941
[TBL] [Abstract][Full Text] [Related]
37. Vitamin K in combination with other biochemical markers to diagnose osteoporosis.
Heiss C; Hoesel LM; Wehr U; Keller T; Horas U; Meyer C; Rambeck W; Schnettler R
Biomarkers; 2004; 9(6):479-88. PubMed ID: 15849068
[TBL] [Abstract][Full Text] [Related]
38. Comparison of the acute alterations in serum bone turnover markers and bone mineral density among women with surgical menopause.
Bahar S; Abali R; Guzel S; Bozkurt S; Guzel EC; Aral H; Boran AB
Eur J Obstet Gynecol Reprod Biol; 2011 Nov; 159(1):194-7. PubMed ID: 21764505
[TBL] [Abstract][Full Text] [Related]
39. [Early, noninvasive diagnostic of osteoporosis in men].
Lepiarz-Rusek W; Kokocińska D
Przegl Lek; 2005; 62(7):641-9. PubMed ID: 16463693
[TBL] [Abstract][Full Text] [Related]
40. Pattern of bone mineral density in idiopathic male osteoporosis.
Laroche M
Rheumatol Int; 2012 Oct; 32(10):3093-6. PubMed ID: 21918900
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
